Epidemiological and clinical characteristics of long COVID-19 among Iranians: A community-based study in southern Iran

Author:

Askarian Mehrdad,Taherifard Erfan,Jazzabi Fatemeh,Shayan Zahra,Assadian Ojan,Groot Gary,Hatam Nahid,Askarian Ardalan,Faghihi Seyed Mohammadebrahim,Taherifard Ehsan

Abstract

Abstract Background The study aimed to evaluate the prevalence and pattern of long COVID-19 (LC) symptoms among individuals who had contracted COVID-19, to calculate the incidence of LC, and to provide insights into risk factors associated with developing LC in this population. Methods This population-based cross-sectional survey was conducted in Fars province in 2023. Adult participants with a history of COVID-19 were recruited using a cluster random sampling method, alongside a control group with similar characteristics through the same methodology. Data were collected through in-person interviews using two researcher-developed data collection forms focused on demographic and clinical information. Results A total of 2010 participants, comprising 1561 (77.7%) and 449 (22.3%) individuals with and without a previous history of COVID-19 were included. Among those with COVID-19 history, the prevalence of experiencing any symptoms was 93.7% (95% CI of 92.3%-94.8%) during the disease acute phase and 36.4% (95% CI of 34.0%-38.8%) after recovery. The incidence of symptoms specifically related to COVID-19, calculated by comparing the symptom rates between participants with and without a history of COVID-19, was found to be 13%. Factors such as older age, previous hospitalization for COVID-19, presence of cardiovascular disease, and use of steroids/chemotherapy were associated with LC symptoms. Conclusions Our investigation sheds light on long-term aspects of COVID-19, demonstrating a significant prevalence of LC with diverse manifestations. It also underscores the importance of establishing standardized criteria and control groups in research on LC to address challenges related to heterogeneity and potential overestimation of symptoms.

Publisher

Springer Science and Business Media LLC

Reference49 articles.

1. CDC. COVID-19 Timeline. Last Reviewed: March 15, 2023 [Cited March 6, 2024]; Available from: https://www.cdc.gov/museum/timeline/covid19.html.

2. Cascella M, R.M., Aleem A, et al. Features, Evaluation, and Treatment of Coronavirus (COVID-19) [Updated 2023 Aug 18]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK554776/.

3. WHO. Number of COVID-19 cases reported to WHO (cumulative total). [Cited December 25, 2022]; Available from: https://data.who.int/dashboards/covid19/cases.

4. IHME. COVID-19 Results Briefing. January 21, 2022 [Cited December 21, 2022]; Available from: https://www.healthdata.org/sites/default/files/files/1_briefing_Global_5.pdf.

5. Marco Cascella, M.R., Abdul Aleem, Scott C. Dulebohn, Raffaela Di Napoli, Features, Evaluation, and Treatment of Coronavirus (COVID-19). Last Update: August 18, 2023, StatPearls Publishing: StatPearls [Internet]. Treasure Island (FL).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3